DK1276896T3 - Epitop-synkronisering i antigen-præsenterende celler - Google Patents

Epitop-synkronisering i antigen-præsenterende celler

Info

Publication number
DK1276896T3
DK1276896T3 DK01930922.8T DK01930922T DK1276896T3 DK 1276896 T3 DK1276896 T3 DK 1276896T3 DK 01930922 T DK01930922 T DK 01930922T DK 1276896 T3 DK1276896 T3 DK 1276896T3
Authority
DK
Denmark
Prior art keywords
housekeeping
disclosed
antigen
cells
presenting cells
Prior art date
Application number
DK01930922.8T
Other languages
Danish (da)
English (en)
Inventor
John J L Simard
David C Diamond
Xiang-Dong Lei
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/561,074 external-priority patent/US6861234B1/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of DK1276896T3 publication Critical patent/DK1276896T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
DK01930922.8T 2000-04-28 2001-04-27 Epitop-synkronisering i antigen-præsenterende celler DK1276896T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56157100A 2000-04-28 2000-04-28
US56046500A 2000-04-28 2000-04-28
US56157200A 2000-04-28 2000-04-28
US09/561,074 US6861234B1 (en) 2000-04-28 2000-04-28 Method of epitope discovery
PCT/US2001/013806 WO2001082963A2 (en) 2000-04-28 2001-04-27 Method of identifying and producing antigen peptides and use thereof as vaccines

Publications (1)

Publication Number Publication Date
DK1276896T3 true DK1276896T3 (da) 2010-10-18

Family

ID=27504814

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01930922.8T DK1276896T3 (da) 2000-04-28 2001-04-27 Epitop-synkronisering i antigen-præsenterende celler

Country Status (12)

Country Link
US (1) US20070269464A1 (enExample)
EP (4) EP1276896B1 (enExample)
JP (1) JP2003535824A (enExample)
CN (1) CN1440462A (enExample)
AT (1) ATE474931T1 (enExample)
AU (3) AU2001257410B8 (enExample)
CA (1) CA2405363A1 (enExample)
DE (1) DE60142615D1 (enExample)
DK (1) DK1276896T3 (enExample)
ES (1) ES2347762T3 (enExample)
NZ (1) NZ521715A (enExample)
WO (1) WO2001082963A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
US7252824B2 (en) 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
EP1595548A3 (en) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-neovasculature preparations for treating cancer
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
CN101024842A (zh) * 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
AU2008229888B2 (en) * 2001-11-07 2012-07-05 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2003270311A1 (en) * 2002-09-06 2004-03-29 Mannkind Corporation Epitope sequences
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
ATE496129T1 (de) 2003-07-22 2011-02-15 Ludwig Inst Cancer Res Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
PL1833506T3 (pl) * 2004-12-29 2016-01-29 Mannkind Corp Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
SG162817A1 (en) 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
AU2006259221B8 (en) * 2005-06-17 2013-02-07 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
CA2643337C (en) * 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP2009544610A (ja) * 2006-07-14 2009-12-17 マンカインド コーポレイション 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法
WO2008035350A1 (en) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2012031076A1 (en) * 2010-09-02 2012-03-08 Ludwig Institute For Cancer Research, Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
AU2012258603A1 (en) * 2011-05-26 2014-01-16 Geneius Biotechnology, Inc. Modulated immunodominance therapy
WO2014039718A1 (en) * 2012-09-05 2014-03-13 Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz Methods for discovering therapeutic targets
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
CN103837688A (zh) * 2014-03-27 2014-06-04 吉林农业大学 一种检测犬猫弓形虫抗体的间接elisa试剂盒
DK3122375T3 (da) 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
US20170266269A1 (en) * 2014-03-28 2017-09-21 University Of Washington Through Its Center For Commercialization Methods of identifying antigens for vaccines
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
EA035419B9 (ru) * 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
CN104142401B (zh) * 2014-07-25 2016-04-20 北京普恩光德生物科技开发有限公司 膀胱肿瘤相关抗原检测试剂盒
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN105067731B (zh) * 2015-06-05 2017-06-16 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
TWI752930B (zh) * 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US20200182884A1 (en) * 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2018217852A1 (en) * 2017-05-23 2018-11-29 Gettysburg College Crispr based tool for characterizing bacterial serovar diversity
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
WO2021176352A2 (en) * 2020-03-03 2021-09-10 Tarek Mohammad Custommune: a web tool for designing personalized and population-targeted peptide vaccines
WO2024050547A2 (en) * 2022-09-02 2024-03-07 Hunterian Medicine Llc Compact bidirectional promoters for gene expression

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
DE68919846T2 (de) * 1988-02-12 1995-07-06 Commw Scient Ind Res Org Poxvirus-vektoren.
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE184704T1 (de) 1989-11-03 1999-10-15 Donald L Morton Nachweismethode für harnkarzinom-assoziierte antigene
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6299295B1 (en) 1997-07-03 2001-10-09 Matsushita Electric Industrial Co., Ltd. Ink jet printing head having ink chambers arranged in succession by lamination
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences

Also Published As

Publication number Publication date
NZ521715A (en) 2008-01-31
EP1276896B1 (en) 2010-07-21
EP2248910A1 (en) 2010-11-10
AU2001257410B2 (en) 2006-08-24
CN1440462A (zh) 2003-09-03
AU2010251790B2 (en) 2013-02-07
WO2001082963A2 (en) 2001-11-08
JP2003535824A (ja) 2003-12-02
CA2405363A1 (en) 2001-11-08
EP1276896A2 (en) 2003-01-22
AU5741001A (en) 2001-11-12
AU2001257410B9 (en) 2006-10-05
ES2347762T3 (es) 2010-11-04
EP2278024A1 (en) 2011-01-26
EP2278023A1 (en) 2011-01-26
WO2001082963A3 (en) 2002-04-11
HK1053333A1 (en) 2003-10-17
AU2010251790A1 (en) 2011-01-06
ATE474931T1 (de) 2010-08-15
AU2001257410B8 (en) 2006-12-21
DE60142615D1 (de) 2010-09-02
US20070269464A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
DK1276896T3 (da) Epitop-synkronisering i antigen-præsenterende celler
NO20015073D0 (no) Vaksiner
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
DK1147117T3 (da) Immunologiske adjuvansforbindelser
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
DK0724432T3 (da) Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
DK1618889T3 (da) Influenzavaccine
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
WO2002009752A3 (en) Immunological adjuvant compounds
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
EA200701440A1 (ru) Композиции для иммунизации против микобактерий
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
BR9306187A (pt) Vacina bacterin-toxóide pasteurella haemolytica tipo a-1
ATE374622T1 (de) Genetische impstoffe mit adjuvans
WO2004002412A3 (en) A method and composition to elicit an effective autologous antitumoral immune response in a patient
Garçon Chance and necessity
CY1117601T1 (el) Ανασυνδυασμενα εμβολια κατα κωπηποδων καλιγιδων (θαλασσιων ψειρων) και αλληλουχιες αντιγονων αυτων
Fragoso et al. A specific vaccine to protect patients with multiple sclerosis from herpes zoster
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
AP2000001938A0 (en) Immune response modulator alpha-2 macroglobulin complex.